Research programme: galectin inhibitors - Galectin Therapeutics

Drug Profile

Research programme: galectin inhibitors - Galectin Therapeutics

Alternative Names: GM series; GM-CT-02; GR series; GR-MD-01; PRO-GR 300

Latest Information Update: 25 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pro-Pharmaceuticals
  • Developer Galectin Therapeutics; Icahn School of Medicine at Mount Sinai; University of Georgia; University of Michigan Medical School
  • Class Carbohydrates; Polysaccharides
  • Mechanism of Action Galectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Fibrosis
  • No development reported Hepatic fibrosis

Most Recent Events

  • 25 Sep 2015 No development reported for Fibrosis in USA (Parenteral)
  • 24 Sep 2015 Research in Cancer and Fibrosis is ongoing in USA (Galectin Therapeutics website, September 2015)
  • 24 Sep 2015 No development reported - Preclinical for Hepatic fibrosis in USA (Parenteral) (Galectin Therapeutics, pipeline, September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top